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CELL DEATH AND GROWTH ARREST PATHWAYS MEDIATING THE ACTIONS
OF STILBENE 5C IN HCT-116 COLON CANCER CELLS
Alotaibi M.R.*1, Xu Di,1 Beckman M.J.2, Lee R. M.3, Gewirtz D.A.1,

Abstract
The stilbene derivative, cis-3, 4’, 5-trimethoxy-3’-aminostilbene (stilbene 5c), is a potentially
potent antitumor agent that acts via binding to the colchicine-binding pocket in microtubules.
Earlier studies have shown that stilbene 5c induces cell death in ovarian cancer cells and
leukemic cells (Lee RM et al, 2008; Lee RM et al, 2008). The present study was designed to
investigate the effectiveness of this microtubule poison against the HCT-116 human colon cancer
cell line and its mechanisms of action. Time course studies demonstrated that stilbene 5c
produces a biphasic decrease in cell viability. The capacity of the cells to proliferate was not
restored upon removal of the drug after 6 days of exposure. Consistent with the results of the
time course studies, β-galactosidase staining indicated that treatment with stilbene 5c also
promotes senescence. In addition to senescence, stilbene 5c-treated HCT-116 cells displayed
formation of autophagic vesicles by acridine orange staining, which was supported by
fluorescence-activated cell sorting (FACS). Further evidence of autophagy was derived from
treatment of HCT116 cells carrying an RFP-LC3 construct with stilbene 5c, in which LC3
puncta formation increased in a time-dependent manner. DAPI staining, TUNEL, and Annexin 5
staining indicated that apoptosis is also occurring in stilbene 5c-treated HCT-116 cells. Cell
cycle analysis demonstrated growth arrest at both G1 and G2/M, and an increase in the subG1
population at days 3 and 5, which correspond to senescence and apoptosis respectively.
Interestingly, DAPI and Hoechst staining revealed morphological changes in the cell nuclei
(binucleated and micronucleated cells), which suggest that mitotic catastrophe may also serve as
a mode of cell death after treatment with stilbene 5c. However, our studies indicated that stilbene
5c works in a p53-independent manner. Exposure of P53-null HCT116 cells to stilbene resulted
in a similar sensitivity as in p53-wild type HCT116 cells. We found that autophagic vacuoles
were formed in response to stilbene 5c in p53-null HCT116 cells as well. Consistent with
previous studies in other experimental cancer models, this work indicates that stilbene 5c could
potentially be effective against colon cancer through the promotion of multiple modes of cell
death.
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Chapter 1: Introduction
I.

Cancer

Cancer is a set of diseases that result from abnormal growth of cells. Under normal conditions,
differentiated cells divide and grow in a controlled manner to replace aged and damaged cells. When
regulatory molecular mechanisms fail to manage the progression and growth of cells, newly developed
abnormal cells will invade and destroy the surrounding tissues. Those abnormal cells gather to form a
mass called a tumor. However, it is not necessarily that all formed tumors are cancers. There are also
non life-threatening benign tumors that can develop by unusual progression of cells. Benign tumors are
generally slower growing than malignant tumors. Also, benign tumors do not have the propensity to
destroy or invade the adjacent organs and tissues, which all malignant tumors do. Cancer can develop
in different organs and tissues, forming different kinds of malignant tumors. Another critical
characteristic of malignant tumors is their ability to spread throughout the body in a process called
metastasis. Metastasis occurs when cells migrate via the circulation and travel through the blood stream
to another site. In the process of metastasis, cancerous cells can cause severe damage to essential
organs such as the liver, the lungs, and the brain. (American Cancer Society)

II.

Statistics

Cancer is a serious health problem in the United States as well as throughout the world.
Annually, one out of four deaths in the United States is cancer-related, signifying a high rate of
mortality [1]. In the United States, 1, 638, 910 new cases of cancer were expected to be diagnosed and
577, 190 cases were anticipated to result in death[1]. The latest report has shown that there is a decrease
in cancer incidence in different races and ethnicities during the last five years, especially in African
American and Hispanics by 2.4% and 2.3%, respectively. Generally, cancers may be induced by natural
radiation sources, environmental mutagens, viral infections, bacterial infections, fungal infections, and
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failure of the immune system to prevent carcinogenesis. New reports indicated that colorectal cancer
incidence is considered the third most common, as well as the third leading cause of death in both
genders during the last few years.

III.

Colorectal Cancer

Colon carcinoma, sometimes called colorectal carcinoma, represents one of the most common
and life-threatening cancers worldwide. Colorectal tumors are usually initiated by the development of
noncancerous polyps in the tissues lining the colon. These developed polyps are subdivided into
different kinds, and the polyps that most likely to develop into cancer are adenomatous polyps.
According to the American Cancer Society (www.cancer.gov), colorectal cancer is considered the third
most diagnosed cancer as well as the third leading cause of cancer-related deaths in both genders in the
US in 2011. Statistically, 141,210 cases are expected to be diagnosed with colorectal cancer and 49,380
deaths are caused by colorectal cancer. More than 20% of the cases presented in the clinic were late
stage colorectal cancer which metastasizes to the liver. Typical therapeutic regimens for colon cancer
include surgery, radiotherapy and chemotherapy. Although this type of cancer can be managed by
surgery and/or chemotherapy, the late stages of colon cancer show high resistance to the current
therapeutics. The first-line treatment of colon cancer includes a combination therapy of 5-flurouracil,
leucovorin, and oxaliplatin or irinotecan with bevacizumab [2]. However, treatment of patients with
currently used chemotherapeutic agents is associated with severe side effects due to their cytotoxic
effects on normal proliferating and resting cells. Hence, searching for new effective anticancer agents is
necessary to overcome these major side effects.

IV.

Microtubule inhibiting agents
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One of the major chemotherapeutic agents used to treat cancer is a class of drugs that interfere
with microtubule function and inhibit normal cell cycle progression. Traditionally, microtubule poisons
are categorized into two major groups: drugs that cause stabilization of microtubules such as taxanes and
epothilones and drugs that destabilize microtubules such as vinca alkaloids and colchicines [3]. These
microtubules inhibitors can also be classified into three classes according to their binding sites on
microtubules [4]. Vinca alkaloids, which include vincristine, vinblastine, and vinorelbin, are effective in
the treatment of haematological malignancies. Paclitaxel and docetaxel belong to a group named taxanes
that are commonly used to treat ovarian cancer as well as breast cancer. Colchicine-site inhibitors are
considered the third group of tubulin-binding inhibitors. Although many agents have been discovered
and classified in the group of colchicines-site inhibitors (CSI), none of these compounds have been
clinically approved. CA4P, a phosphorylated form of combretastatin, and ZD6126 have been tested in
phase I human clinical trials and phase II for combretastatin only [5]. Clinical trials of these agents have
shown their propensity to work as vascular disrupting agents (VDAs); however, CSIs have shown
serious side effects such as neurotoxicity and cardiovascular toxicity [6-8]. Therefore, development of
new colchicine-binding inhibitors with fewer side effects is important to effectively improve the
therapeutic impact of outcomes of colchicine-site inhibitors.

V.

Stilbene compounds

Stilbene derivatives are a group of compounds that have established biological actions such as
cell growth suppression and anti-vascular activities. A widely known agent of this group is transresveratrol (trans-3, 4’, 5-trihydroxystilbene), a hydroxylated stilbene, that is found in grapes and
possesses a beneficial effect in coronary artery disease [9]. Several studies have shown that resveratrol
inhibits tumor cell proliferation in vitro and tumor vascularization in vivo leading to tumor growth
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suppression [10]. Another example of biologically active stilbenes is combretastatin which is a natural
cis-stilbene isolated from the South African tree Combretum caffrum. Previous studies have shown that
combretastain has potent anticancer properties via binding to tubulin, which in turn causes endothelial
cell damage and neovascular disruption [11]. The structures of these compounds have been modified by
Simoni et al., to synthesize therapeutically active analogs of reservatrol by the addition and removal of
functional groups on the basic chemical structure [12]. This work resulted in the synthesis of many
different compounds with variable potencies. Stilbene 5c and 6c were identified as the most two active
compounds among them.
One of these newly developed compounds is cis-3, 4', 5-trimethoxy-3'-aminostilbene
(stilbene 5c), a very potent inducer of tumor cell death via binding to the colchicine-binding
pocket in microtubules [13]. This compound induces apoptosis in HL60 and U937 leukemic cells
without producing cytotoxicity in normal haematopoietic progenitor cells at similar
concentrations [14-15]. Also, stilbene 5c showed a very potent antitumor activity in SKOV3
ovarian cancer cells at low concentrations [14]. In vivo and in vitro studies have proven that
stilbene 5c does not affect normal perfusion but disrupts the tumor vascularization, showing high
selectivity against cancerous cells [16]. Moreover, stilbene 5c has a relatively wide therapeutic
index; in vivo studies of stilbene 5c have indicated that the neurotoxicity starts at 100 mg/kg
without observing cardiac or bone marrow toxicity, while a dose of 25 mg/kg has shown a
therapeutic effect against ovarian cancer in treated mice [14]. In addition, the pharmacokinetic
studies of stilbene 5c in tumor xenograft model indicated that the drug has an average half-life of
1.8 hours, Cmax 2,302 ng/mL and clearance 32.9 L/h [16]. In this study, the concentration of
stilbene 5c was detected in brain, liver, spleen, heart, lung, kidney and plasma. Stilbene 5c levels
were undetectable in lung, heart and spleen at 1 hour after the injection, but levels of stilbene 5c
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in brain, liver and kidney were determined at 1 hour and significantly decreased 3 hours post
injections. On the other hand, stilbene 5c was maintained accumulated in both plasma and tumor
cells.
Stilbene 5c is thought to induce its anticancer effect in a cell cycle-dependent pathway since the
drug is a microtubule poison. Stilbene 5c has been shown to block the progression of the cell cycle at the
G2/M phase in several cell lines at low concentrations, while cell death was seen at higher doses [14]. A
previous study indicated that stilbene 5c enhances the production of reactive oxygen species (ROS)
through disturbing electron transport chain complex in mitochondria, which ultimately leads to cell
death [14].

VI.

1)

Responses to drug treatment

Apoptosis
Apoptosis was first defined in 1972 by Kerr, Wyllie, and Currie to explain the

characteristic aspects of programmed cell death [17]. It is a mode of cell death that takes place
throughout the development as well as the growth and the aging of an organism. Apoptosis is
considered to serve as a protective mechanism and healthy process that regularly occurs in living
tissues to maintain the number of normal cells in that system in response to exposure to harmful
signals or disease insults [18]. The morphological aspects of the dying cells have been
differentiated between cells undergoing apoptosis and cells in necrosis. Unlike necrosis,
apoptosis results in the reduction of cell size, cell nucleus, and rupture of nucleus and its
chromatin, while oncotic necrosis is characterized by swelling and karyolysis [19]. Also,
apoptosis is a controlled and energy-dependent cell death, which can occur in individual cells as
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well as group of cells, whereas necrosis is a passive and uncontrolled process that can be due to
e.g. a nonspecific injury to the cell membrane.
There are two types of apoptosis: physiologic and pathologic apoptosis. Either in
physiological or pathological conditions, apoptosis can result from different types of stimuli
affecting cellular signaling mechanisms and lead to a consequential cell death. It appears that
apoptosis is a cell type specific process; that is some cell types are resistant to certain stimuli,
while other cells may interpret the same stimuli as a trigger for death pathway induction.
Physiologic apoptosis is an essential phenomenon that has been characterized in many human
systems through developmental stages and adulthood in normal and disease states such as in the
immune and nervous systems to kill pathogen-infected cells and overproduced cells [20-21].
Molecular mechanisms of programmed cell death are explored and well known.
Apoptosis is an irreversible mode of cell death that involves caspase activation inside the cell
and ends by engulfment of the apoptotic cell by macrophages. The process of apoptosis is
composed of three phases that include initiation, effector, and degradation, where markers of
apoptosis can be clearly identified. During this process, pro-apoptotic proteins stimulate
upstream caspases to activate downstream effector caspases. Caspase cleavage leads to DNA
cleavage by endogenous DNases that cut double strand DNA into fragments [22].
Apoptosis can be triggered by extrinsic and intrinsic pathways, where the former utilizes
death ligand-death receptor binding, and the latter can be triggered by toxins or radiation. The
extrinsic pathway involves the activation of a death receptor from the tumor necrosis (TNF)
superfamily e.g. TRAIL. By activation, the adaptor molecule Fas-associated death domain
(FADD) recruits caspase 8 and then initiates apoptosis via the cleavage of caspase 3 or 7. The
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intrinsic pathway is generally triggered by the release of cytochrome c, smac/DIABLO, or
apoptosis inducing factor (AIF) from the inner membrane of mitochondria. When a stress signal
is initiated, those released mitochondrial proteins activate effector caspases and lead to
subsequent DNA fragmentation [22].
It is noteworthy to mention that apoptosis plays a major role in various diseases.
Dysregulations of programmed cell death is considered pathologic apoptosis that leads to many
diseases such as cancer, autoimmune lymphoproliferative syndrome, AIDS, ischemia, and
neurodegenerative diseases like Alzheimer’s disease and Huntington’s disease. Therefore, it is
important to understand the molecular basis of apoptosis either to achieve a therapeutic effect of
a drug or to better know how biological systems respond to abnormal cell division.

2)

Autophagy
Autophagy is a biological process that is induced upon nutrient deprivation and/or

cellular stress. During autophagy, intracellular and extracellular nutrients are sequestered into
autophagosomes and transported to the lysosomes to be degraded, recycled, and then reused by
the cell. Autophagy plays key roles in regulation of cellular homeostasis by breaking down old
or misfolded proteins, maintaining the viability of starving cells by producing amino acids, and
protecting cells against pathogenic infections by the engulfment of a pathogen [23-25]. Cells
that undergo autophagy are characterized by enlargement and swelling of nuclei with formation
of acidic vacuoles. Although the role of autophagy is still debatable, several reports indicated
that autophagy is a protective process induced to maintain cellular viability in response to
harmful insults [26-28].
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Promotion of autophagy is highly regulated by different genes and advances through
several steps: induction, autophagosome nucleation, and completion, by which formed
autophagosomes fuse with lysosomes for protein breakdown [29]. During the first phase, the
Atg1 complex, which includes Atg1, Atg13, and Atg17 as well as other factors, is activated to
initiate autophagy [30]. Then, class-III phosphatidylinositol-3-kinase (PI3K) and Beclin-1/Atg6
activation is required to collect parts of cytoplasm and other organelles and build up a doublemembraned autophagosome. After that, LC3 protein is cleaved by Atg4 protease and lipidated by
phosphatidylethanolamine (PE) via Atg7 and Atg3 proteins to form LC3-PE. Following LC3
cleavage, the Atg12/Atg5/Atg16 complex regulates the binding of LC3-PE to the
autophagosomal membrane [31-33]. Finally, formed autophagosomes unite with acidic
lysosomes, which results in the decomposition of autophagosomes-sequestered proteins [25-26].
An important regulator protein of autophagy is the mammalian protein kinase mTOR,
which is the target of rapamycin. mTOR protein is a serine/threonine kinase that is activated
under healthy growth conditions and induces gene translation and synthesis of necessary
proteins. During starvation and nutrients deprivation, the mTOR pathway becomes inactivated
and autophagy is promoted [34]. Also, PI3K pathway functions upstream of mTOR to contribute
to autophagy induction [35-36]. This pathway is shown to be activated due to nutrient
deprivation but not in response to conventional chemotherapy. Therefore, it could be valuable
studying the activation of these pathways by the effects of microtubule inhibitors.

3)

Senescence
Senescence is considered to be an irreversible growth arrest of cells. During senescence,

the cells’ shape and morphology become flattened and enlarged with decreased pH and enhanced
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β-galactosidase activity [37]. Generally, senescent cells show resistance against mitogenic and
apoptotic signals [38]. Senescence occurs as a result of oncogenic stress, DNA damage, or
cytotoxic drugs [39]. However, irregular senescence is associated with the development of
certain diseases such as atherosclerosis, osteoarthritis, muscular degeneration, ulcer formation,
Alzheimer’s dementia, diabetes, and immune exhaustion [40]. On the other side, defective
signaling pathways of senescence may lead to unlimited growth of cells, which may ultimately
form a tumor. The ability of these cells to become immortal results from the fact that cancer cells
are capable of escaping from the regulated lifetime of somatic normal cells. Thus, cellular
senescence is thought to be a tumor suppressing process as it stops infinite cellular divisions
[41].
To determine a finite number of cell divisions, the term “Hayflick limit” is used as a
reference for how many times a normal cell will divide. Every chromosome has a structure at the
end of its DNA called the “Telomere” which contain repeat of the sequence TTAGGG [42-43].
The telomere is not replicable, and therefore becomes reduced after each cell division. The
decrease in telomere length eventually limits the ability of cells to divide. Therefore, the
reduction in telomere length is considered as an important factor in the regulation of replicative
senescence [44].
Senescence can be induced via many pathways [40], but the two major pathways that are
involved in senescence are: p14ARF/p53/p21 pathway and the INK4/CDK/pRb pathway [45]. In
the first pathway, the protein p14ARF negatively regulates MDM2, which originally
ubiquitinates p53, and thus causes activation of p53 [46]. Consequently, the p53 protein acts
upstream of a CDK inhibitor p21, leading to growth arrest and senescence [47]. Also, p53 has
other downstream targets to promote cellular senescence such as 14-3-3 and GADD45 that
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inhibit G2/M transition and downregulation of myc [48]. In the pRb-dependent pathway,
senescence-inducing signals activate p16INK4a that inhibits the function of CDKs. The pRb
protein is known to be inactivated by CDKs; consequently, p16INK4 activation promotes Rb
dephosphorylation and Rb activation to bind to members of the E2F family of transcription
factors, which results in cellular senescence [49-50]. Furthermore, there is a cross-talk between
these two pathways. The protein p21, which is upregulated by p53, promotes senescence either
directly by the first pathway or through the inhibition of CDK in the second pathway [51].
Senescence can be telomere-dependent or –independent. Telomeres are gradually lost in
each S phase of cell cycle, resulting in loss of DNA at the very end of chromosomes. Also, some
cells lack the ability to reactivate telomerase, the enzyme responsible for the addition of DNA
sequence repeats at the end of chromosomes [52-53]. Existence of erosions at telomeric sites
leads to the generation of a persistent DNA damage response and growth arrest [54-56]. In
addition, nontelomeric DNA breaks can induce senescence and growth arrest via persistent DNA
damage response [57].
Senescence can also occur independently of the DNA damage response. Several reports
have indicated that p21WAF1 and p16INK4a can induce cells to undergo senescence with no
DNA damage response [55, 58]. A kind of stress called “Culture shock’’ induces senescence
with no erosions of the telomeres [59]. This group of stresses includes hyperphysiological
oxidation and the presence of serum instead of plasma. Furthermore, loss of Pten phosphatase
also causes growth arrest of cells without induction of the DDR signaling pathway [60].
Although stilbene 5c is not a DNA damaging agent like some anticancer drugs and
ionizing radiation, it could induce senescence through the activation of some tumor suppressor
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genes. Many reports indicated that some microtubule poisons lead to cell division failure
accompanied with activation of check points [61-62]. Therefore, it is worthy to study whether
stilbene 5c promotes senescence in HCT116 colon carcinoma cells.

4)

Mitotic catastrophe
Mitotic catastrophe is a term used to describe a mode of cell death resulting from

dysregulated mitosis, usually resulting in the formation of cells with multiple nuclei. During
mitotic catastrophe, clusters of aneuploidy and missegregated chromosomes are formed and
enclosed within the nuclear envelope. The formation of the nuclear envelope results in the
enlargement of treated cells with the presence of multiple micronuclei, as a distinct feature of
mitotic catastrophe. Also, mitotic catastrophe induction can be determined through the
expression of mitosis-related genes. This faulty mitosis occurs as a result of disconnection
between the phase of DNA replication and mitosis during cell cycle progression. Thus, it is still
controversial whether mitotic catastrophe is a mode of cell death or a phenomenon that leads to
cell death via apoptosis or necrosis [63]. It is worth mentioning that cancer cells need to escape
apoptosis to develop malignancy. Despite the differences between mitotic catastrophe and
apoptosis, several reports have shown that drug-induced mitotic catastrophe is associated with
the release of pro-apoptotic proteins and activated caspases, indicating similarity in signaling
pathways, or at least a cross-talk between apoptosis and mitotic catastrophe [64-66]. Many
reports have shown that mitosis-regulating proteins have been changed in response to antitumor
drugs, thus leading to an aberrant mitosis and nuclear division [67-69]. The clinical significance
of mitotic catastrophe as a mode of cell death is derived from evidence of mitotic catastrophe
formation beside other modes of cell death in cancer patients treated with antitumor drugs [67,
70-71]. Several anti-microtubule agents such as vinca alkaloids and taxanes have been shown to
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promote mitotic catastrophe probably by mitotic spindles distruption [71-72]. Given the fact that
stilbene 5c is a microtubule poison, it is important to address whether this drug induces mitotic
catastrophe in HCT116 cells.
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Chapter 2: Materials and methods
2.1 Cell culture
HCT-116 colon cancer cells were purchased from ATCC and maintained in 10% DMSO
(Sigma Chemical, St. Louis, MO) with Fetal Bovine Serum (FBS) (GIBCO Life Technologies,
Gaithersburg, MD) and stored frozen in liquid nitrogen until ready for use. Cells were defrosted
and cultured in a T75 flask (Cellstar) in RPMI 1640 medium with 5% fetal bovine serum, 5%
bovine calf serum, 2 mM L-glutamine, and penicillin/streptomycin 0.5 mL/100 mL medium
(10,000 units/mL penicillin and 10 mg/mL streptomycin (GIBCO Life Technologies,
Gaithersburg, MD) and incubated at 37ºC, 5% CO2, in a moisturized environment. When cells
reach 80% confluency, cells are washed with 1X PBS (GIBCO) and harvested by 0.25% trypsinEDTA (GIBCO) (incubation for 5 minutes). Trypsin is deactivated by addition of 5 mL of
serum-containing RPMI 1640, cells are collected and centrifuged at 1,500 rpm for 5 minutes.
Media and trypsin are removed and 5 mL of new sterile medium is added to the pellet; cells are
resuspended and 500 µL of suspension is placed into 96 mm³ plate filled with 10 mL of RPMI
1640 medium. In every experiment, cells are cultured under identical conditions and incubated
overnight to allow for adherence before treatment with continuous drug exposure. Stilbene 5c
preparations were kindly provided by Dr. Ray Lee’s laboratory at Virginia Commonwealth
University. Drug was diluted in autoclaved DMSO (Sigma Chemical, St. Louis, MO) aliquots at
concentrations of 30 mM and 300 µM. Used drug was not thawed more than twice due to the
stability of the drug.
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2.2 Clonogenic Survival assay
The ability of cells to form colonies was evaluated by plating 200 cells in 6-well plates
for control,1% DMSO, 10 nM of stilbene 5c, and 30 nM of stilbene 5c, and 2000 cells for 100
nM of stilbene 5c, 300 nM of stilbene, and 600 nM of stilbene 5c. Cells were permitted to adhere
for overnight. The next day, cells were treated with the indicated concentrations for 2 days, drug
was removed and fresh media was added every other day. At day 9, cells were washed one time
with 1X PBS before fixation with 100% of methanol for 10 minutes. Methanol was aspired and
colonies were stained with crystal violet dye (1%) in deionized water for 10 minutes. Colonies
were counted visually in each well.
2.3 MTT dye assay for cell viability
In 96-well plates, 200 µL of medium containing 6000 cells was added to each well and
left to attach overnight prior to drug treatment. After 72 hours of drug exposure, media was
aspired and MTT solution (2 mg/mL PBS made up in the dark) was added to each well and
incubated at 37ºC for 3 hours. The MTT dye becomes reduced to insoluble formazan inside
living cells. 100 µL of DMSO was added for 5 minutes to each well to dissolve the blue dye.
Absorbance was read at 490 nm (KC Junior software, EL800 Universal Microplate Reader).
2.4 Time course of drug toxicity and its impact on cell viability
Cells were cultured in 6-well plates in equal number and left overnight for attachment.
The next day, cells were treated with drug and the number of viable cells was counted on daily
basis for 5 days. At every time point, drug was removed and cells were washed one time with 1X
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PBS. Then, 350 µL of 0.25% trypsin was added to every well for harvesting and incubated for 5
minutes, then deactivated by 650 µL of fresh media, to make up 1 mL of cell suspension. Cells
were collected in 1 mL conical tubes (Eppendorf) and 10 µL of cell suspension was added to 10
µL of trypan blue and injected in chamber slides (invitrogen) and counted using Countess
Machine (invitrogen). A compromised cell membrane will allow trypan blue to penetrate inside
the cell, indicative of loss of viability.
2.5 Assessment of apoptosis by DAPI staining
At indicated time points, both adherent and non-adherent cells were collected and
centrifuged at 1,500 rpm for 5 minutes. Medium was removed and cells were resuspended in 1
mL of fresh medium. Cells were then diluted to 40,000 cells in 200 µL of 1X PBS and the same
volume was loaded per slide. Prepared slides were spun at 3,000 rpm for 5 minutes (Shandon
Cytospin 4, Thermal Electron Corp). Slides were kept in refrigerator until ready for experimental
use. At the day of staining, cells were fixed at room temperature with 4% formaldehyde in 1X
PBS for 10 minutes. Slides were then rinsed in 1X PBS for 10 minutes. Acetic acid was diluted
in ethanol (1:2 dilution) and used to fix cells at 20ºC for 5 minutes and then washed with 1X PBS
for 5 minutes. 10 µL of Vectashield:Dapi (1:1000 dilution) was prepared and added to every
slide. Nail polish was used to seal slides with cover slips. Images were taken using an Olympus
1X 70 microscope and an Olympus SC 35 type camera. Three different experiments were
visualized and assessed.
2.6 TUNEL assay for apoptosis
Another method of assessments of apoptosis is by detecting DNA fragmentation via
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). For this assay, cells
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were harvested and collected at various time points and centrifuged at 1,500 rpm for 5 minutes.
Medium was removed and cells were resuspended in fresh media. A dilution of 40,000 cells in
200 µL per slide was prepared and cells were spun at 3,000 rpm for 5 minutes (Shandon
Cytospin 4, Thermal Electron Corp). Slides were kept refrigerated at 4ºC until ready for use. On
day of staining, cells were washed with PBS and then fixed with 4% formaldehyde in PBS for 10
minutes at room temperature. Cells were then washed twice with PBS for 5 minutes and fixed
with 1:2 of acetic acid and ethanol for 5 minutes at 20ºC, and washed again with PBS.
ImmunoPen was used to surround cells and hold solutions. After that, cells were blocked with
BSA diluted in PBS in a ratio of 1 mg/ml for 30 minutes. Slides were rinsed twice in PBS and
enzyme mixture composed of 5X buffer, terminal transferase, 25mM CoCl2, fluorescein-12dUTP
and deionized water, was added for staining for an hour in incubator. After two washes with
PBS, slides were topped with cover slips and images were taken under the flourescenct
microscope. The same slides could be used for DAPI staining by mounting with Vectashield:
DAPI (1:1000) before cover slips.
2.7 Annexin 5-PI staining for apoptosis
In cells undergoing early apoptosis, phosphatidyl serine (PS), which is originally located
in the inner cell membrane, transfers to the outer cell membrane. Translocated phosphatidyl
serine (PS) can be bound with Annexin V attached to a fluorescent chromophore (FITC) to
identify early apoptosis. Propium iodide (PI) penetrates non-intact cellular membranes and stains
cells, serving as a marker of late apoptosis or necrosis. In this experiment, cells were plated
overnight to permit cells to adhere. On the following day, cells were treated with the drug. At
several time points, adherent and non-adherent cells were harvested by 0.25% trypsin and
centrifuged at 2,000 rpm for 5 minutes. Cells were then resuspended in 1 mL of 1X PBS,
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transferred to 2 mL tubes, and centrifuged at 2,000 rpm for 5 minutes. PBS was removed and
100 µL of 1X binding buffer (BD Biosciences) was added to pellets per tube. 5 µL of AnnexinFITC (BD Biosciencec) and 5 µL of PI at 10 µg/mL (BD Biosciences) were then added per tube.
In the dark, cells were softly vortexed and incubated for 15 minutes at room temperature. Before
anaysis by flow cytometry, 400 µL of 1X binding buffer was added per tube and samples were
analyzed by flow cytometry technique as soon as possible to measure the fluorescence at 530
nM.
2.8 Hoechst Staining for mitotic catastrophe
Both adherent and non-adherent cells were both harvested at indicated time points and
centrifuged at 1,500 rpm for 5 minutes at 5ºC. Supernatant was removed and the cell pellet was
resuspended in 5 mL of PBS diluted to 40,000 cells in 200 µL, and refrigerated. On the day of
staining, cells were fixed with 0.075 M KCL for 8 minutes at room temperature, and then
washed with 1X PBS. A 1:3 dilution of methanol and glacial acetic acid was prepared and slides
were rinsed in solution for 20 minutes and then washed with deionized water and allowed to dry
overnight. Cells were stained with Hoechst dye of 2 µM in nanopure water for 10 minutes and
slides were topped by cover slips and images were taken by the same tools as for DAPI and
TUNEL. Mitotic catastrophe was evaluated according to the formation of bi- and micronucleated
cells.
2.9 Evaluation of autophagy by acridine orange staining
200,000 cells were seeded in 6-well plates and permitted to adhere overnight and drugtreated the next day. At various time points, drug was removed and cells washed once with 1X
PBS. Acridine orange dye was diluted in PBS in a ratio of 1:10000 (prepared in the dark) and
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added to cells for staining, and incubated for 15 minutes. Dye then was aspired and plates were
washed with 1X PBS and fresh medium was added. Photographs were taken with an Olympus
1X 70 microscope and an Olympus SC 35 camera.
2.10 Transfection of HCT116 cells with RFP-LC3
The Tolkovosky laboratory has generated the RFP-LC3 construct [73]. Frozen
cells were thawed, centrifuged, placed in a fresh medium, and passaged many times before
transfection. 1x10 6 cells were collected in a pellet and resuspended in 100 µL of the
Nucleofector V mix (Nucleofector kit V, Amaxa). A microgram of the RFP-LC3 vector was
added to the suspension. The whole entire suspension was transferred to a cuvette, which then
was placed in the nucleofector device to run program D-32 and transfect the cells. Transfected
cells were then mixed with 500 µL of warm medium and transferred to a Petri dish. Gentamycin
8ng/mL was used to maintain a stable transfection.
2.11 Measurement of acridine orange staining by flow cytometry for autophagy
Flow analysis was utilized to count the cell population positively stained with acridine
orange. Treated cells were harvested, collected, and centrifuged at speed of 1500 rpm.
Supernatant was removed and pellets were resuspended in 1 mL of fresh medium. Cell
suspension was filtered through standard flow cytometry 40 micron filter (BD falcon). A
10:1000 dilution of acridine orange in 1X PBS was prepared (in the dark) and protected from
light until ready for use. At flow cytometry, 10 µL of acridine orange solution was added to per
sample to make the dilution of 1:10000. When analyzed by flow cytometry, the acridine orange
dye is excited at wavelength 525 nM for green flourescence and 620 nM for red fourescence.
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2.12 Senescence by β-Galactosidase staining
Detection of senescence was by β-Galactosidase staining after exposure to the drug
treatment. Cells were washed once with 1X PBS and fixed with 2% formaldehyde/ 0.2%
glutaraldehyde for 5 minutes. Fixing solution was aspired and PBS was used again to wash and a
staining solution composed of 1 mg/mL 5-bromo-4-chloro-3-inolyl-β-galactosidase in
dimethylformamide (20 mg/mL stock), 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM
citric acid/sodium phosphate, 2 mM MgCl2, at pH 6.0 was added and the cells were incubated
overnight at 37ºC. The following day, cells were washed twice with PBS and pictures were
taken.
2.13 Quantification of β-Galactosidase staining using flow cytometry for senescence
On the day of staining, old media was washed out and 100 nM of bafilomycin A1 in fresh
media was added to the treated cells to induce lysosomal alkalinization and left incubated at 37ºC
and 5% CO2 for 1 hour. After incubation, C12FDG working solution was added to each well in
amount to make the final concentration 33 µM and was continued incubation for another 1 hour.
Media was then aspired and cells were washed twice with PBS. Cells were harvested and
collected for centrifugation at speed 1500 rpm and resuspended in PBS. C12FDG is a substance
that hydrolyzed by upregulated β-galactosidase enzyme and becomes fluorescent at wavelength
of 500–510 nM.
2.14 Cell cycle analysis
Cells were seeded overnight to adhere. The next day, supplemented medium was
removed and serum depleted medium was added and left for 24 hours to synchronize all cells at
the same phase. On day 0, cells were treated with stilbene 5c. At the indicated time points, viable
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and non-viable cells were harvested and collected. Cells were centrifuged at 1500 rpm and
supernatant was aspired. Pellets were resuspended in PBS for wash and centrifuged at 1500 rpm
again. After removing supernatant, 0.2 mL of PBS was added and pellets were resuspended very
well in order to obtain a single cell suspension. 1.8 mL of cold 70% ethanol was added gradually
per tube into the cell suspension and vortexed very well. Cell suspensions were stored at 4ºC
until ready for use. On day of staining, cells were centrifuged from ethanol and PBS was added
for wash. PBS was removed and staining solution was added to the pellets 2 hours prior to flow
cytometry. Staining solution contains 0.1% (v/v) Triton-X-100 in 10 mL PBS, 2 mg of DNasefree RNase A, and 0.2 mL of the propium iodide stock (1 mg/ml).
2. 15 Assessment of antitumor effect of stilbene 5c in vivo
B16F10 melanoma cell line is murine malignant tumor cells that can be injected in the
C57BL/6 mouse to form a syngeneic model. This cell line was chosen for its ability to
metastasize into the lungs. In this study, mice were injected with 1x105 tumor cells/mouse on day
29. In the following day, mice were intraperitoneally injected with the drug once a day, five days
a week, for two weeks. The drug was diluted in a vehicle containing Tween, Ethanol, and saline
in a ratio of 2:1:7 respectively. Sentinel mice were used to monitor the formation of tumor
nodules onto the lungs. At certain time point, mice were sacrificed and the lungs were removed
and saved in Bouin’s solution, a common fixative solution used to preserve tissues. The tumor
burden in mice was assessed based on two parameters. The first parameter is the visual counting
of how many black nodules have been formed in each lung. The second parameter was used is
the calculation of the surface area of each nodule. Measurement of the latter parameter was
performed by embedding lung tissues into paraffin, sectioned at 4 microns thickness and stained
with Hematoxylin and Eosin. Images of stained nodules were taken under the microscope and
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the surface area of each tumor nodule was calculated using Nanozoomer computer software
(Olympus).
2. 16 Western blotting
In order to determine whether some proteins were induced, degraded, or downregulated,
we conducted a specific assay to analyze protein levels. After the indicated time points, we
collect viable and non-viable cells in a pellet. These collected cells were mixed with 100 to 200
µL of 1X Tris lysis buffer (1 M Tris (pH 6.8), 10% SDS, and dH2O) containing protease
inhibitors and boiled for 5 minutes. Protein concentration was measured using the Bradford
protein assay (BioRad) and 40 µg of total cell lysate was separated in a 12% gel using SDSPAGE. Proteins were transferred onto nitrocellulose membrane for 1.5 hours and washed 3 times
with PBS containing 0.01% Tween for 5 minutes in each time. Membrane was blocked for one
hour with TBS-Tween 20 buffer containing 5% nonfat dry milk. The proteins were then blocked
with the primary antibody and left overnight in 4ºC. In the following day, the primary antibody
was washed out and the immunoflourescent secondary antibody was added for an hour at room
temperature. Membrane was washed three times and bands were detected using enhanced
chemiluminescence detection reagents from Pierce (Rockford, IL).
2. 17 Statistical analysis
Statistics were performed using ANOVA followed by post-hoc analysis. The significance
of group values was determined based on a p-value of p<0.05.
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Chapter 3: Results

3.1 Stilbene 5c produces growth arrest and cell death in HCT116 colorectal cancer cells.
Previous reports have shown that stilbene 5c was effective in promoting cell death and
growth arrest at nanomolar concentrations, 30 nM and 100 nM, showing high potency against
both leukemic and ovarian cancer cells [8-9]. Figure 1 show that continuous exposure of
HCT116 cells to 0, 30, 100, 300, and 600 nM of stilbene 5c for 72 hours resulted in reduced
numbers of viable cells in a dose-dependent manner, with a significant cell viability decrease at
100 nM, 300 nM, and 600 nM by approximately75%, 80%, and 84%, respectively. Consistent
with our observation in the MTT assay, treatment of HCT116 colon carcinoma cells with
stilbene 5c for 48 hours with the same indicated concentrations resulted in a 90% decline in
colony formation starting at 100 nM (Figure 2). This concentration is relevant to the plasma
concentration that has been shown previously in the pharmacokinetic studies of stilbene 5c in
mice [16]. Based on these findings, we have chosen to continue our work with 100 nM as our
effective concentration to further investigate the mechanisms of drug’s cytotoxicity. In order to
understand whether stilbene 5c induces cell killing or growth arrest, we assessed the effects of
stilbene 5c on cell viability over a period of five days in a time course study. Figure 3
demonstrates a decrease in number of viable cells in a time course treatment when exposed to
100 nM stilbene 5c. Twenty-four hours post treatment, extensive cell death was observed in the
treated groups. Thereafter, the treated tumor cell populations showed an apparent prolonged
growth arrest. To assess whether treated HCT116 cells were able to recover their capacity to
proliferate, drug was washed out on day 5 and fresh medium was added and replaced every other
day for an additional 10 days. These experiments demonstrate that the residual surviving tumor
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cell population had lost its capacity to recover, pointing toward an irreversible growth arrested
state.
3.2 Induction of irreversible senescence and loss of proliferation
In previous studies, UCI-101 and SKOV3 ovarian cancer cells and HL60 and U937
leukemic cells displayed a growth suppression and cell cycle arrest at G2/M upon treatment with
stilbene 5c [8,9]. In our time course study, cells treated with 100 nM of stilbene 5c have shown
cell death followed by growth arrest during days 2, 3, and 4. In addition, residual cells did not
show proliferative recovery after drug removal by 10 days (Figure 4). Therefore, we decided to
determine whether senescence was promoted in response to the treatment with stilbene 5c. βgalactosidase staining was performed 72 hours post treatment and visualized by microscopy.
Treated groups showed morphological markers of senescence such as granulations, flattening,
and spreading of cells. Also, the treated cells demonstrated positive staining with bluish green βgalactosidase color (Figure 5). The intensity of β-galactosidase staining was further quantified by
flow cytometry technique on days 2 and 4 (Figure 6A). A significant fraction of the treated cell
populations was apparently shifted to the area of positive staining with a rightward move of the
histogram peak on day 4, but not on day 2. In addition to the quantification of β-galactosidase
staining, flow cytometry technique also was used to measure the size of cells. Treated HCT116
colon carcinoma cells on days 2 and 4 were remarkably enlarged compared to control (Figure
6B), showing consistency with our microscopic observations. Taken together, senescence was
initiated in HCT116 cells as early as 48 hours after initiating the treatment with stilbene 5c.

3.3 Promotion of autophagy by Stilbene 5c in HCT116 cells
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Autophagy is a regulated process in which misfolded proteins and damaged cellular
components are broken down by lysosomal enzymes in double-membrane enclosures. Some
literature reviews and studies indicate that extensive autophagy is defined as type II programmed
cell death. However, a recent study showed that the process of autophagy is an important
mechanism that leads to senescence [74]. In addition, previous studies from our laboratory
demonstrated that autophagy and senescence were induced in HCT116 cells in response to
another colchicine site-binding inhibitor, JG-03-14. Since stilbene 5c induced senescence in
HCT-116 colon carcinoma cells, we then sought to establish whether senescence might be
preceded by autophagy. A number of different approaches and tools including acridine orange
staining, RFP-LC3 redistribution, and p62 degradation were utilized to address this question.
During autophagy, acidified autophagosomes fuse with lysosomes to form acidic
vacuoles, which are stainable by acridine orange dye. Figure 7 shows that control HCT-116 cells
have a single orange circle per cell located approximately in the same site in the cytoplasm,
indicating a relatively high basal level of autophagy that may be induced in HCT-116 cells due to
activated ras protein [75]. Cells treated with 100 nM of stilbene 5c displayed different large
number of stained vacuoles per cell that increased in a time-dependent manner. In addition, cells
exposed to 100 nM of stilbene 5c became enlarged in comparison with control cells,
demonstrating a morphological sign of autophagy. An additional flow cytometry technique used
to evaluate autophagy in cells based on the intensity of acridine orange staining was used in our
studies. In this experiment, we found that treated cells showed a significant increase in the
percentage of the cell population falling into the area red-fluorescing cells (5.3 ± 3.03 with
control, 25.07 ± 6.26 with treatment; p<0.05), indicating cells undergo autophagy when treated
with stilbene 5c (Figure 8).
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We also monitored the localization of the LC3-II protein in HCT116 colon carcinoma
cells. LC3-I is a cytoplasmic protein that converts to LC3-II when lipidated and binds to
autophagosomal membranes during autophagy. On days 1, 2, and 3, RFP-LC3 - transfected
HCT-116 cells were visualized by flurescent microscopy. As shown in figure 9, promotion of
autophagy was confirmed by RFP-LC3 redistribution. Whereas control cells show one small
diffuse fluorescent punctuate per cell, red puncta were clearly increased and distributed in the
treated cells.
Autophagic flux was also measured via p62 degradation, a protein sequestered in
autophagosome and degraded by lysosomal hydrolases [76]. HCT116 colon cancer cells treated
with 100 nM stilbene 5c were tested for p62 decomposition by immunoblotting. Level of p62
clearly declined 48 hours post treatment (Figure 10).

3.4 Evaluation of apoptotic cell death induced by stilbene 5c
One of the desirable outcomes of therapeutic treatment of cancer is the promotion of
apoptosis. We evaluated apoptosis in HCT116 cells in response to 100 nM of stilbene 5c via
different assays including DAPI staining, TUNEL assay, and Annexin V-PI staining. Even
though we observed cell death during the first day in our time course study, we failed to find any
evidence of apoptosis 24 hours after the treatment with stilbene 5c in our annexin V–PI staining
experiment (Figure 12). Dramatically, a significant part of the treated cell population shifted
toward early and late apoptosis on days 3 and 5 (4.2 ± 3.63 with control, 3.533 ± 0.321 with Day
1, 19.6 ± 4.6 with Day 3, 19.6 ± 1.77; p<0.05 control versus Day 3 and Day 5). To confirm the
induction of apoptotic cell death in cells treated with stilbene 5c, we stained cells with DAPI and
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TUNEL to characterize apoptosis markers under the fluorescent microscope. Although DAPI
staining barely shows nuclear shrinkage or distortion in treated groups, TUNEL images for the
same samples presented fluorescence of fragmented DNA, indicating that HCT116 cells undergo
apoptosis upon drug treatment (Figure 11).

3.5 Assessment of mitotic catastrophe by stilbene 5c
In addition to apoptosis, there is another form of aberrant mitosis – caused cell death
known as mitotic catastrophe. Several reports have shown that mitotic catastrophe might
characterize a mitotic form of apoptosis [65, 77]. In our assessment of apoptosis markers by
DAPI staining, we found that some cells have abnormal nuclear morphology that was obviously
enlarged with multipolar structure. We then plated HCT116 cells in 6-well plates and treated
them with 100 nM stilbene 5c. Cells were then stained directly with DAPI while they were in the
plates. Images of DAPI confirm mitotic arrest in treated cells as shown by the appearance of
more than a single nucleus in one cell (Figure 13). Therefore, we performed another experiment
called Hoechst staining to ensure that this finding is not only restricted to DAPI staining as well
as to prove that mitotic catastrophe is induced in stilbene 5c-treated cells. Figure 14 demonstrates
that treated cells have bi- and micronuclei with the presence of DNA fragments as an indication
of mitotic catastrophe induction.

3.6 Stilbene 5c induces p53-independent cell death
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Due to the appearance of multiple modes of cell death in HCT116 cells in response to
stilbene 5c, we then sought to investigate the role of the wild-type p53 gene in HCT116 cells and
the involvement of this protein in the antitumor action of stilbene 5c. The tumor suppressor gene
p53 plays major roles in cell mechanisms that respond to a genotoxic stress such as the induction
of cell cycle arrest at G1/S phase and the initiation of apoptosis signaling pathways. It has been
widely known that cells lack wild-type p53 have the capability to evade apoptosis and become
more likely to be resistant to anticancer therapy. Thus, one of the most desirable effects of an
antitumor agent is to be working regardless p53 status since more than 50% of tumor cell lines
are p53 mutant. In order to understand the function of p53 in our system, we treated HCT116
(p53 -/-) cells with 100 nM stilbene 5c and evaluated the cell viability in a time course study.
(p53 -/- HCT-116) cells showed equal sensitivity to stilbene 5c as in the p53 wild-type HCT-116
cells, indicating that stilbene 5c does not require a wild-type p53 gene to produce its anticancer
effect (Figure 16).

3.7 Induction of autophagy in HCT116 (p53 -/-) and HCT116 (p53 +/+) cells
As we observed that stilbene 5c is also effective in p53-null HCT116 cells, we wanted to
identify the early mode of cell death in those cells. Our previous results indicated that apoptosis
was not evident in HCT116 (p53 +/+) cells until day 3. Therefore, it was important to perform
similar studies in the p53 null cells using acridine orange staining to determine whether
autophagy is induced in order to better understand the role of autophagy in our system. We found
that extensive autophagy is promoted at the same extent in both p53-null and wild type cells
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during the first three days (Figure 17). This finding may point toward the probability of
autophagic cell death in HCT116 cells as a result of stilbene 5c treatment.

3. 8 Low dose of stilbene 5c does not disrupt tumor vascularization and fails to inhibit metastasis
of B16F10 melanoma cells in C57BL/6 mice
The effectiveness of stilbene 5c was also examined in B16F10 cells and was shown to
promote cell death at concentrations of 30nM and 300nM in vitro (Figure 18). Both
concentrations resulted in more than 90% of cell killing over a period of five days. B16F10
melanoma cells showed sensitivity to the microtubule poison, JG-03-14, at concentrations of 250
nM and 500 nM (Figure 19). Our studies further indicated that both stilbene 5c and JG-03-14
induce autophagy and senescence, but not apoptosis in melanoma cells (Figure 20, Figure 21).
We evaluated the effect of intraperitoneal administration of stilbene 5c and JG-03-14 at nontoxic doses 25 mg/kg and 200 mg/kg, respectively. B16F10 melanoma cells were chosen for this
assay due to the susceptibility of these cells to travel through the circulation and metastasize onto
the lungs to form dark nodules. C57BL/6 mice were injected intravenously with B16F10
melanoma cells and mice were then treated with 25 mg/kg/day five days a week for two weeks.
In this study, neither stilbene 5c nor JG-03-14 prevented the invasion of B16F10 melanoma cells
into the lungs according to the number of tumor nodules (64.375 ± 51.5 with vehicle, 83.25 ±
55.257 with 25 mg/kg/day stilbene 5c and 52.125 ± 47.7 with 200 mg/kg/day JG-03-14; n=8)
(Figure 22). We further measured the surface area of each nodule to assess whether stilbene 5c or
JG-03-14 disrupts the vascular perfusion of the tumor. Lungs were sectioned at thickness of 4
microns and embedded into Eosin and Hematoxylin and nodules sizes were measured and
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analyzed. While JG-03-14 induced a significant decrease of average nodule size, our calculations
revealed that a non-significant reduction in tumor volume resulted from the treatment with
stilbene 5c (0.0518 mm3 ± 0.006416 with vehicle, 0.0403 ± 0.00972 with stilbene 5c, and
0.02145 ± 0.004113 with JG-03-14, p = 0.0573, vehicle vs treated, n = 6) (Figure 24).
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Figure 1. Sensitivity of HCT116 cells to stilbene 5c. Viability of HCT-116 colon cancer cells
to stilbene 5c was measured by the MTT assay. 6000 cells were plated in 96-well plates and
continuously exposed to the indicated concentrations of stilbene 5c for 72 hours. MTT dye was
added to each well and cells were incubated for an additional 3 hours. DMSO was then used to
dilute the precipitated MTT dye and the absorbance was read at wavelength 490 nM. This
experiment was done in triplicate and error bars represent standard deviation (* p<0.05 compared
to control)
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2.
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Figure 2. Determination of sensitivity to stilbene 5c based on clonogenic survival. HCT116
cells were plated in 6-well plates and treated with the indicated concentrations for 48 hours. Drug
was washed out and cells were supplemented with fresh medium every other day for an
additional 7 days. Number of colonies in each well was counted and calculated as a percentage
of control. This experiment was performed in triplicate and error bars represent standard
deviation (* p<0.05 compared to control)
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Figure 3. Time course study of HCT116 cells after continuous exposure to100 nM stilbene
5c. HCT-116 cells were plated in 6-well plates and treated with 100 nM of stilbene 5c over a
period of 5 days. Cells were harvested and collected and viable cell number was determined by
trypan blue exclusion assay using the automated Countess cell counting device. Cells were plated
in triplicate for each condition. This experiment was performed in different times (* p<0.05
compared to control)
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Figure 4. Continous exposure to stilbene 5c leads to loss of proliferation. The time course
study shown in figure 3 was extended for 10 more days post treatment. On day 5, the drug was
removed and remaining cells were supplemented with fresh medium every other day until day
15. At indicated time points, cells were harvested with trypsin and counted using trypan blue
exclusion assay. This experiment was performed in triplicate.
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Figure 5. Chronic treatment of 100 nM stilbene 5c promotes senescence in HCT116 colon
carcinoma cells. HCT116 cells were plated in 6-well plates and exposed to 100 nM of stilbene
5c. The drug was then removed and cells were incubated with staining buffer and X-gal for
overnight. Using electron microscopy at the magnification power of 20X, the morphological
markers of senescence were obvious with a remarkable increased blue color stain observed in
treated cells. The result was confirmed by three different experiments.
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Evaluation of intensity of β-Galactosidase staining in HCT-116
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Figure 6. Assessment of induced senescence by quantification of β-galactosidase staining
intensity in stilbene 5c-treated HCT116 cells. In addition to the classical microscopic method,
induction of senescence could be assessed by flow cytometry to measure the fluorescence of βgalactosidase staining and size of cells. Data presented in the graph were generated based on the
percentage of cells that were positively stained with β-galactosidase in both treated and nontreated conditions i.e cell population in P2 area of Panel A. In panel B, treated cells showed a
rightward shift, indicating an increase in the size, complexity and granularity of treated cells.
This experiment was performed in triplicate (* p<0.05 compared to control)
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Figure 7. Evaluation of autophagy induction by acridine orange staining.
Cells were plated and treated with 100 nM of stilbene 5c. At indicated points, acridine orange diluted in
medium in a ratio of 1:10000 was added to cells. During autophagy, acidic vacuoles are stained with
acridine orange dye. Images were taken under a fluorescent microscope at a magnification power of
200X. Three different experiments were performed to confirm the result.
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Quantification of autophagy induced in HCT116 cells in response to St. 5c
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Figure 8. Quantification of intensity of autophagy by flow cytometry.
Cells were treated with 100 nM stilbene 5c for 3 days. Cells were then harvested and centrifuged
at 1500 rpm. Acridine orange was diluted in PBS in a ratio of (1:10000) and was then added to
the cells for staining. The extent of autophagy was counted based on the number of cell
population in quadrants Q2 and Q4 from our raw data. This experiment was performed three
times (* p<0.05 compared to control)
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Figure 9. Stilbene 5c promotes the formation of red puncta with LC3-II in RFP-LC3
HCT116 colon cancer cells. HCT116 cells were transfected with an RFP-LC3 vector and plated
in 6-well plates. Cells were then treated with 100 nM stilbene 5c for up to 3 days. At each time
point, drug was removed and cells were washed with sterile PBS. Images were taken under a
fluorescent microscope with a magnification power of 20X. Cells undergoing autophagy are
characterized by increased number and size of red puncta with a remarkable enlargement of
cells.
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Figure 10. Degradation of p62 protein after treatment of HCT116 cells with 100nM stilbene 5c.
Completion of autophagy process was confirmed via the degradation of p62 by western blotting.
HCT116 human colon cancer cells were treated with 100nM stilbene 5c for 24 and 48 hours and levels
of p62 protein was measured. A clear degradation was obvious in response to 100nM stilbene 5c.
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Figure 11. Assessment of apoptosis by detection of DNA fragmentation using the TUNEL assay.
HCT116 colon carcinoma cells were exposed to 100 nM stilbene 5c for 3 days. Cells were then loaded
on slides, stained by DAPI/TUNEL, and covered by cover slips. Images were taken under a fluorescent
microscope using a magnification power of 200X. DAPI stain is used to localize the nuclei in both
treated and non-treated cells. The fluorescent dots represent the fragmented sites on DNA, which are
considered a hallmark of apoptosis. Two different experiments were performed to confirm the result.

53

12. A.

Control

Day 1

Day 3

Day 5

B.

% of apoptotic cells

30

Measurement of apoptosis by Annexin 5 staining

25

*

*

Day 3

Day 5

20
15
10
5
0
Control

Day 1

54

Figure 12. Stilbene 5c induces apoptosis in HCT116 colon cancer cells.
Cells were treated with 100 nM stilbene 5c for one, three, and five days and stained with Annexin V and
PI to assess whether cells die via apoptosis and/or necrosis . The raw data show four quadrants; wherein,
Q1 corresponds to necrotic cells only, Q2 reflects the late apoptotic cell population, Q3 indicates cells
that neither apoptotic nor necrotic cells, and Q4 indicates early apoptosis. The percentage of apoptotic
cells presented in Panel B is counted based on percentage of cells in both Q2 and Q4. This experiment
was performed twice (* p<0.05 compared to control)
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Figure 13. Mitotic catastrophe is promoted in HCT116 cells in response to 100 nM stilbene 5c.
HCT116 colon cancer cells were plated in 6-well plates and treated with the indicated concentration. At
the indicated time points, drug was washed out and a dilution (1:10,000) of DAPI in PBS was added to
stain the nuclei. Images were taken under a fluorescent microscope with magnification power of 200X.
Markers of drug-induced mitotic catastrophe are characterized by bi-nucleated and micro-nucleated
cells. This experiment was done in triplicate.
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Figure 14. Stilbene 5c – treated HCT116 cells undergo mitotic catastrophe cell death.
Images shown in this figure represent HCT116 colon carcinoma cells treated with 100 nM stilbene 5c
for three days. Cells were then collected and loaded on cover slips on which nuclei were stained with
Hoechst dye. In control cells, nuclei are separated and well rounded; whereas, treated cells nuclei appear
abnormal in size with more than one nucleus in the same proximity due to the failure to fall apart as well
as clear bi-nucleation, indicating the induction of mitotic catastrophe. This experiment was performed
twice.

59

15.

Control

Day 1

Day 3

Day 5

60

Figure 15. Cell cycle analysis demonstrates growth and cell death in HCT116 colon cancer cells
after exposure to 100 nM stilbene 5c. Cells were plated in 6-well plates and allowed to adhere
overnight. Serum-deficient medium was added overnight to synchronize the cells at the same phase. On
day 0, drug was added to treatment wells and control cells were supplemented with fresh medium. At
each time point, cells were trypsinized and the experiment was performed as explained in chapter 2.
Cells were arrested at the G2/M phase 24 hours post-treatment with an increase in the sub-G1 population
in time-dependent manner. Images in the right column show the same distribution of cells but in
normalized cell count (Y) axis. This experiment was performed twice.
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Figure 16. Similar response of p53-null HCT116 cells and p53-wt HCT116 cells to 100 nM stilbene
5c.
The p53-null HCT-116 cells were plated in 6-well plates and treated with 100 nM of stilbene 5c over a
period of 5 days. Cells were harvested and collected and viable cell number was determined by trypan
blue exclusion assay using the automated Countess cell counting device. Cells were plated in triplicate
for each condition. This experiment was performed in three different times (* p<0.05 compared to
control)
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Figure 17. Promotion of autophagy in p53-null HCT116 colon cancer cells after exposure to 100
nM stilbene 5c. Both p53-null and –wild type HCT116 colon cancer cells were plated in 6-well plates
and treated with 100 nM stilbene 5c. At indicated time points, drug was removed and cells were stained
with acridine orange for 15 minutes. Images were taken under a fluorescent microscope at magnification
power of 20X. This experiment was performed in triplicate.
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Figure 18. Inhibition of colony formation in B16F10 melanoma cells by stilbene 5c.
150 cells of B16F10 cells were plated per well in triplicate in 6 well plates. Control cells were
seeded at the same density and allowed to incubate in drug free medium while cells treated with
3nM, 30nM, 300nM and 1000nM stilbene 5c were incubated for 72 hours. Drug containing
medium was removed at the end of the 72 hours and replaced with fresh medium. When colonies
of at least 50 cells are visible to the naked eye, cells were stained with crystal violet and counted
visually. The number of colonies formed decreased in a dose-dependent manner in cells treated
with stilbene 5c compared to control cells. (# p<0.05 compared to control)
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Figure 19. A dose-dependent decrease in colony formation in B16F10 in response to JG-0314.
B16F10 cells were plated at a density of 100 cells/plate for DMSO, JG 10 nM and 500 cells/plate
for JG 250 nM and JG 500 nM. Assay shown is a representative experiment performed in
triplicate that was corrected for plating efficiency. Two identical replicate experiments were
performed for confirmation. Error bars represent standard deviations and significant differences
from DMSO treatment are indicated by * (P<0.05)
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Figure 20. Stilbene 5c and JG-03-14 induce extensive autophagy in B16F10 melanoma cells.
Acridine Orange staining was utilized to assess the induction of autophagy in B16F10 cells
treated with 300nM stilbene 5c and 500nM JG-03-14. Cells were plated, incubated overnight and
treated the following day with either 300nM stilbene 5c or 500nM JG-03-14. Acridine Orange
images were taken using an inverted fluorescent microscope. Induction of autophagy was
apparent due to the orange puncta distribution in the treated cells.
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Figure 21. JG-03-14 and stilbene 5c promote senescence in B16F10 melanoma cells.
B16F10 cells were treated with 500nM JG-03-14 and 300 nM stilbene 5c for 72 hours in two
individual studies. Drug was washed out and cells were stained with β-galactosidase as a marker
of senescence. Images were taken at the magnification power of 200X.
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Figure 22. Stilbene 5c did not suppress the metastasis of B16F10 melanoma cells in C57BL/6 mice.
B16F10 melanoma cells that are syngeneic in C57BL/6 mice were injected intravenously. Drug was
administered intraperitoneally once per day for five days a week over a period of two weeks. The
vehicle used was a mixture of ethanol, tween and saline in a ratio of 2:1:7. Adriamycin was used as a
positive control. The efficacy of drug was measured according to the number of dark nodules
metastasized to the lungs. (* p<0.05 compared to control, n = 8)
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23. Evaluation of the effect of stilbene 5c on tumor growth and vascular perfusion. The surface area
of each nodule was measured by staining the tumor nodules with Hoechst stain. Images of the nodules
were taken microscopically and nanozoomer computer software (Olympus) was used to measure the
surface area of each nodule. The average nodule size was calculated per mouse for six mice per each
group. Non-significant reductions in the surface area were induced by stilbene 5c.
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Figure 24. Images of B16F10 tumor nodules metastasized to mice lungs. Lung tissues were paraffin
embedded, sectioned at 4 microns thickness and stained with Hematoxylin and Eosin. Tumor nodules
appear darker when stained with 1H&E. Also, dark nodules are considered cancerous as they show
melanin pigments and abnormal nuclear shape when they were observed by nanozoomer computer
software.
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Chapter 4: Discussion
4.1 Overview
Microtubles are dynamic proteins that play major functions in trafficking, signaling, division,
and migration in eukaryotic and mammalian cells. These proteins are found in both interphase and
dividing cells. Therefore, many microtubules inhibitors were developed and evaluated for their activity
against multiple diseases such as malaria and cancer [78].
Different microtubule poisons have been utilized to treat various forms of cancer. The
mechanism of microtubule poisons’ action is thought to be by the alteration of microtubule dynamics.
Vinca- and Colchicine-binding inhibitors destabilize microtubule depolymerization; while, taxanes
increase polymerization at high doses. Vinca alkaloids and taxanes were discovered more than 40 years
ago and have been used effectively in the treatment of different solid and haematological malignancies
[79-81]. However, many colchicine-binding inhibitors have been screened in vitro, in vivo, and in
clinical trials, but none of them has been clinically approved for any therapeutic indication yet due to
their severe neuro- and crdiotoxicities [14]. Moreover, microtubule inhibitors appear to be active in
disrupting tumor perfusion. These agents target tumor vascularization by the inhibition of proliferation
and migration, key role functions of microtubule, of newly formed endothelial cells. Resistance to these
agents can be developed by numerous mechanisms including cellular efflux of the drug, alterations at
the binding site of the drug, and inability to induce apoptosis in treated cells. Previous studies of stilbene
5c showed this drug disrupts tumor perfusion without affecting normal organ perfusion, leading to
decrease of blood and oxygen to tumor cells [16]. Also, stilbene 5c was found to promote apoptosis in
ovarian and leukemic cancer cells in vitro. [14-15]. In this study, we sought to evaluate the anticancer
properties of stilbene 5c on HCT116 colon carcinoma cells and investigate induced modes of cell death.
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4.2 Cell death
Initial experiments were designed to identify effective concentrations of stilbene 5c in HCT116
cells. Cells were treated with 10nM, 30nM, 100nM, 300nM, and 600nM of stilbene 5c. According to
our observations in clonogenic survival assay, 100nM stilbene 5c reduced the number of colonies
formed by 90%. This concentration of stilbene also induces cell death in HCT116 cells based on a
reduction in cell viability of approximately 75%. In both experiments, neither 10nM nor 30nM affected
cellular proliferation or the number of colonies formed after the treatment compared to controls. This
finding suggests that lower concentrations of stilbene 5c are not sufficient to inhibit colchicine-binding
site on tubulin.
HCT-116 cells were treated with 100nM stilbene 5c in order to understand the behavior of HCT116 cells
post-treatment in a time course study. A time dependent decrease in cell viability was observed starting
within 24 hours after treatment. Two days post-treatment, the remaining live cells underwent prolonged
growth arrest for the remaining time course of the study. . The failure of re-growth appears to be
irreversible due to the incapability of treated cells to reproduce after drug removal. This state of growth
arrest demonstrates consistency with clonogenic survival assay findings, which might indicate that cells
respond to stilbene 5c by undergoing senescence after cell death.
4.3 Apoptosis
Previous studies of stilbene 5c in leukemia and ovarian cancer in vitro models revealed that cells
die primarily through apoptosis [14-15]. As shown by time course study, extensive cell death occurs
early after the exposure of HCT116 colon cancer cells to stilbene 5c. We have mentioned earlier that the
deficiency in apoptotic signaling pathways can lead to the development of resistance to microtubule
poisons. HCT116 colon cancer cells have a wild-type p53 protein and proficient caspase enzymes. All of
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these facts indicated that it was of importance to investigate whether apoptosis represents a primary
mode of cell death. While there was no evidence of apoptosis within 24 hours post treatment, treated
cells clearly showed an increase in apoptosis by 25% after 72 hours of exposure to the drug. This finding
was confirmed by the TUNEL assay, where many nuclei had fragmented DNA. To further understand if
the wild-type p53 plays a key role in the triggering of apoptosis in HCT116 cells in response to stilbene
5c, we treated HCT116 p53 (-/-) cells, in which apoptosis signaling pathways activation are less likely to
be induced, with the drug and monitored cell viability over a period of 5 days. The p53-knock out cells
responded similarly to stilbene 5c, sugesting that apoptosis is not primarily induced upon exposure to the
drug. However, p53-mediated apoptosis is triggered by DNA damaging agents [82], and the previous
studies of stilbene 5c revealed that this drug does not have DNA damaging properties [14]. Thus, we
conclude that stilbene 5c induces cell death in a p53-independent manner and that there are modes of
cell death other than apoptosis induced in stilbene 5c-treated HCT116 cells.
4.4 Mitotic catastrophe
Several antitumor agents, including microtubule poisons, can trigger mitotic spindle check points
[83]. It has been shown that anti-microtubule agents induce mitotic arrest-associated cell death [84-85].
For instance, combretastatin A4, a colchicine-binding inhibitor, was found to promote a phenomenon of
cell death related to mitotic catastrophe [86]. One of the interesting findings of previous stilbene 5c
studies was that Chk2 deficient cells become more sensitive to stilbene 5c [14]. Some studies in the
literature pointed out that activation of Chk2 proteins prevents the cell from entering the cycle by downregulating Cdc2/cyclin B complex [87]. According to this inhibitory effect of this protein, it is
speculated that mitotic catastrophe can be negatively regulated by Chk2. Treatment of Hela cells with
debromohymenialdisine (DBH), a chemical inhibitor of Chk2, led to the promotion of mitotic
catastrophe associated with markers of apoptosis [65]. In our study, we found that some cells failed to
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complete the process of cytokinesis when stained with DAPI. This observation appears consistent with
the previous findings of the cytotoxic effect of stilbene 5c on ovarian cancer cells [14]. Also, Hoechst
staining confirmed that prolonged treatment of HCT116 cells results in frequent multiple micronuclei, a
hallmark of mitotic catastrophe. These observations may indicate that the early seen cell death is
generally not due to apoptosis, but rather through mitotic catastrophe. However, recent reports have
shown that mitotic catastrophe characterizes another form of apoptosis [65, 77]. Other reports indicated
that apoptosis becomes initiated after the slippage of cells from mitotic catastrophe [84, 88]. Moreover,
several in vivo and in vitro studies have indicated that mitotic catastrophe is associated with the release
of pro-apoptotic proteins and activation of caspases, which suggests that induction of mitotic catastrophe
requires some pathways involved in mechanisms of apoptosis [64-66] This might explain why markers
of apoptosis appear three days after the treatment with stilbene 5c.
Treatment of p53-null HCT116 cells resulted in a decrease in cell viability to an extent similar to that
observed in the wild type p53 HCT116 cells. Some reports have argues that the p53 gene is required to
induce apoptosis or senescence, but not the mitotic catastrophe [71]. Moreover, it has been thought that
cells lacking functional p53 protein undergo forms of cell death rather than apoptosis such as mitotic
catastrophe and necrosis [63]. Taken together, we conclude that HCT116 cells may primarily undergo
mitotic catastrophe in response to the treatment with stilbene 5c. As a result, apoptosis appears after the
promotion of mitotic catastrophe due to the cross-talk between these processes.

4.5 Induction of autophagy
Autophagy is a catabolic process in which the cell’s contents are broken down by lysosomal
degradation. It is established that HCT116 colon carcinoma cells have constitutively active PI3K and ras
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mutant genes [89]. A study by Gou et al proved that cells with a mutated ras gene, including HCT116
cells, require autophagy to survive [71]. Thus, HCT116 cells have a relatively high basal level of
autophagy. Until today, it is still ambiguous what amount of autophagy is needed to induce cell death.
Also, it is still indistinguishable what signaling elements are responsible for the promotion of autophagic
cell death rather than cytoprotective autophagy. One of the suggested mechanisms by which autophagy
becomes initiated is through the interaction with microtubules. Although the function of microtubules in
the induction of autophagy is not well understood, some studies have shown that microtubules play a
role in autophagosomal formation [90]. The same study demonstrated that autophagosomal level was
increased by more than two fold when cells were treated with vinblastine [84]. In contrast, drugs
stabilizing microtubule polymerization, such as paclitaxel, failed to increase acidic vacuoles. These
results may indicate that microtubules are not essential for autophagosome development, but at least can
contribute to the increase of amount of autophagosomes. Our observations suggest that the obvious
increase in the amount of acidic vacuoles in response to stilbene 5c may be due to its effects on
microtubule dynamics.
Induction of autophagy was confirmed by monitoring microtubule associated protein light chain
LC3 expression in HCT116 cells. LC3-II, a marker of autophagy, is produced by proteolytic cleavage of
LC3-I, and required for the formation of autophagosomes [91]. We found that stilbene 5c increased the
number of RFP punctate pattern in treated cells as early as day 1 compared to control. This finding
supports the idea that autophagy is initiated earlier than other modes of cell death. More importantly,
acridine orange and RFP-LC3 transfection only indicate the induction of autophagy but not the
completion of this process. Thus, another experimental technique has been used as an indicator for
autophagic flux. We have monitored the level of p62 after the incubation of HCT116 cells with stilbene
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5c as early as day 1. We found a clear degradation of p62 after the treatment, indicating that autophagy
has been going to completion.
A recent study showed that curcumin induces autophagy in HCT116 cells in both p53-wild type
and p53-deficient HCT116 cells [92]. Consistent with this finding, we have found that p53-null HCT116
cells incubated with stilbene 5c expressed a similar extent of autophagy as the p53-wild type HCT116
cells. This result strongly suggests that stilbene 5c promotes autophagy in a p53-independent manner,
and may also lead to autophagic cell death.
Although the cross-talk between autophagy and apoptosis is not very well understood, an
interaction between apoptosis and autophagy has been illustrated by many studies. A study by Ding et
al indicating that Bax-positive HCT116 cells undergo autophagic cell death followed by apoptosis [93].
In the same study, it was found that inhibition of autophagy led to apoptosis in Bax-proficient HCT116
cells but not the Bax-deficient HCT116 cells, indicating that presence of Bax is important for switching
the mode of cell death to apoptosis. Another study by Yousefi et al demonstrated that the overexpression
of the ATG5 gene in human cancer cells enhances their sensitivity to undergo autophagic cell death
followed by apoptosis when treated with ceramide or DNA-damaging agents [94]. In this study, when
the ATG5 gene was knocked out, the susceptibility of these cells to die through autophagy was
eliminated with a significant reduction in apoptotic markers. This linkage between autophagy and
apoptosis can possibly be due to the cleavage of ATG5. When the cell becomes exposed to excessive
autophagic stress, calpain proteins cleave ATG5 to produce a fragment that loses its autophagypromoting activity and gains its pro-apoptotic activity [94]. This released fragment translocates into the
mitochondria, where it binds to BCL-XL proteins and promote apoptosis. Also, there is another
mechanism by which the ATG5 protein switches mode of cell death from autophagy to apoptosis. ATG5
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gene can bind to FADD (Fas-associated via death domain) via its C terminus, which in turn stimulates
caspase-dependent apoptosis [95].
In our results, we found that apoptosis was preceded by induction of both autophagy and mitotic
catastrophe. We have discussed the possibility of how mitotic catastrophe leads to the induction of
apoptosis. Here, we show another possibility where triggered autophagy can eventually lead to apoptotic
cell death. For this reason, we expect that autophagy has the capacity to be cytotoxic in this system more
than being cytoprotective. This finding can be of clinical utility, since some tumor cells have the ability
to evade apoptosis. thereby showing resistance to the currently used therapeutics [41, 82].
4.6 Senescence
Several studies have shown that induction of autophagy is associated with promotion of
senescence in cancer cells [74, 92]. Lu et al found that autophagic cell death led to growth arrest in a
xenograft model of ovarian cancer cells [96]. Also, the inhibition of autophagy was found to delay, but
not completely inhibit, the induction of cellular senescence after exposure to an antitumor agent [70,
89]. It appears that autophagy plays a dual role either to induce senescence or promote apoptosis in
response to the treatment with stilbene 5c. Due to this linkage between both these phenomena, we
anticipate that the promotion of autophagy in stilbene 5c-treated HCT116 cells may lead cells to transit
into senescence. Our time course treatment studies showed that treated cells apparently undergo a state
of growth arrest initiated two days post treatment. In addition, cell cycle analysis revealed a growth
arrest at phase G2/M within 24 hours post treatment, with cell killing represented by a sub-G1
population. Also, our β-galactosidase staining indicated that the surviving population showed signs of
senescence following induced autophagy, as cells were enlarged and flattened. Taking into account that
tumor cells need to evade the step of senescence to maintain growth [97], we found that the residual
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surviving cells failed to recover after replenishment with drug-free medium for 15 days in an extended
proliferative recovery study. All of these findings point toward an additional potential therapeutic
outcome of stilbene 5c, preventing the re-growth of cancer cells after exposure.
4.7 Antimetastatic and vascular disrupting properties of stilbene 5c
Beside their roles in cell division and proliferation, microtubules play major functions in
trafficking and migration in mammalian cells. Metastasized tumor cells require migration of cancer cells
and formation of new blood vessels to enrich the tumor site with blood supply and oxygen for growth
and development. Both of these processes are essentially mediated by microtubules and can be easily
distorted by targeting tumor vasculature [98]. Several antiangiogenic studies have shown that these
functions were abrogated by microtubule poisons [99-100]. In addition, two well-known colchicinebinding inhibitors have been identified as vascular-disrupting agents [101]. Another study indicated that
stilbene 5c, a colchicine-site inhibitor, disrupts tumor vascular perfusion, but not the normal organ’s
blood supply [16]. In this regard, we have studied the antiangiogenic and antimetastatic properties of
stilbene 5c and JG-03-14, microtubule poisons that bind to the colchicine-binding site, on B16/F10
melanoma in a syngeneic mouse model. While neither stilbene 5c nor JG-03-14 showed an
antimetastatatic effect according to the number of tumor nodules on the lungs, JG-03-14, but not the
stilbene 5c, significantly reduced the volume of these nodules, indicating that JG-03-14 disrupts the
vascular perfusion of tumor. Although the effect of stilbene 5c was barely remarkable but nonsignificant, we anticipate that higher doses of stilbene 5c are likely to disrupt tumor perfusion. The
reason why JG-03-14 showed a significant effect could be due to either the higher dose used compared
to stilbene 5c, or different pharmacokinetic properties. . This finding may indicate that both JG-03-14
and stilbene 5c are specific for angiogenesis via targeting endothelial cells as shown with
combretastatin, an agent of the same group [16, 102].
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4.8 Future studies
Our results showed that the drug stilbene 5c induces multiple modes of cell death and growth in
HCT116 colon carcinoma cells. These results led us to the next aims of this study in which inhibitors of
autophagy and apoptosis can be used to investigate what modes of cell death are essentially induced. To
further explain what primary cell killing mechanisms are responsible for the effects of stilbene 5c, we
can utilize select pharmacological agents to inhibit the process of autophagy and determine how this
would influence the toxicity of stilbene 5c. Chloroquine and Bafilomycin A-1 have been used to
inhibit fusion of the autophagosome and lysosomes, preventing the last step of autophagy [103]. Also,
we can transiently silence essential autophagy-regulating genes such as ATG5, ATG7, and Beclin-1.
However, these approaches to inhibit autophagy might not clarify the exact role of autophagy due to
the appearance of other mechanisms of cell death concurrently with autophagy i.e. shutting down one
mechanism will enforce cells to die via another pathway.
In additional experiments, use of inhibitors of of caspase cleavage, which would block the
induction of apoptosis, could identify the contribution of apoptosis to drug action. Based on our results,
we found that apoptosis was induced after the appearance of other modes of cell death. This may
illustrate for us that promotion of apoptosis is a consequence of excessive stress. Thus, using Z-Vad may
allow us to differentiate between cytotoxic and cytoprotective roles of autophagy in HCT116 cells.
It would be useful if we also assessed apoptotic cell death and mitotic catastrophe in p53-null
HCT116 cells. We found that stilbene 5c induces both cell death and autophagy in p53-knock out
HCT116 cells. We can perform DAPI and TUNEL assays to assess apoptotic cell death in p53-defecient
cells. However, Annexin V staining could be useful to quantify numbers of cells undergoing apoptosis.
Moreover, it would be worthwhile to perform Hoechst staining to evaluate the intensity of mitotic
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catastrophe induction in p53 (-/-) HCT116 cells. These suggested assays and studies may clearly answer
the question of what primary modes of cell death are particularly induced by stilbene 5c.
Finally, we would evaluate the effectiveness of stilbene 5c on HCT116 colon cancer cells in
vivo, using an orthotopic model [104]. In the previous studies of stilbene 5c, the drug showed efficacy
against HL60 and U937 cells in vivo [15]. IV injections of this drug at doses of 10, 50, and 100 mg/kg
resulted in 22, 62 and 58% apoptosis respectively. In addition, 100 mg/kg of drug extensively killed
central tumor cells with permitting the survival of viable cells at the peripheral areas of the tumor [16].
In this in vivo study, stilbene 5c was found to be tolerated in mice at doses as high as 100 mg/kg,
indicating that stilbene 5c could be a promising VDA due to its low cardiotoxicity. Taken together, the
anti-proliferative and the vascular disrupting properties may suggest that stilbene 5c is an effective agent
for the therapy colon cancer.
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